{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.580","value":"2.75"},{"groupId":"OG001","spread":"4.508","value":"6.71"},{"groupId":"OG002","spread":"4.833","value":"10.38"}]}],"title":"Change from Baseline at Week 1 [N=63; 64; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.779","value":"10.25"},{"groupId":"OG001","spread":"4.705","value":"12.55"},{"groupId":"OG002","spread":"5.001","value":"18.31"}]}],"title":"Change from Baseline at Week 4 [N=63; 64; 58]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.930","value":"4.53"},{"groupId":"OG001","spread":"4.859","value":"14.52"},{"groupId":"OG002","spread":"5.163","value":"22.83"}]}],"title":"Change from Baseline at Week 8 [N=62; 63; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.610","value":"4.49"},{"groupId":"OG001","spread":"4.549","value":"16.62"},{"groupId":"OG002","spread":"5.000","value":"16.20"}]}],"title":"Change from Baseline at Week 12 [N=62; 63; 54]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.608","value":"5.40"},{"groupId":"OG001","spread":"4.537","value":"15.82"},{"groupId":"OG002","spread":"4.823","value":"15.80"}]}],"title":"Change from Baseline at EOT [N=63; 64; 58]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 1, 4, 8 and 12","title":"Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Voided Volume Per Micturition","type":"SECONDARY","unitOfMeasure":"mL"}